NEUEXCELL

Serial Number 97087345
734

Registration Progress

Application Filed
Oct 22, 2021
Under Examination
Apr 11, 2023
Approved for Publication
Feb 14, 2023
Published for Opposition
Feb 14, 2023
Registered

Attorney Assistance

NOA E-Mailed - SOU Required
Due: Apr 11, 2026 90 days
Statement of Use required (all extensions used)

Trademark Image

NEUEXCELL

Basic Information

Serial Number
97087345
Filing Date
October 22, 2021
Published for Opposition
February 14, 2023
Drawing Code
4

Status Summary

Current Status
Active
Status Code
734
Status Date
Oct 24, 2025
Application
Pending
Classes
005

Rights Holder

NeuExcell Therapeutics Inc.

03
Address
Suite 242
401 N. Broad St
Philadelphia, PA 19108

Ownership History

NeuExcell Therapeutics Inc.

Original Applicant
03
State College, PA

NeuExcell Therapeutics Inc.

Owner at Publication
03
Philadelphia, PA

Legal Representation

Attorney
Lawrence M. Green

USPTO Deadlines

Next Deadline
90 days remaining
NOA E-Mailed - SOU Required
Due Date
April 11, 2026

Application History

34 events
Date Code Type Description Documents
Oct 24, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Oct 24, 2025 EX5G S SOU EXTENSION 5 GRANTED Loading...
Aug 22, 2025 EXT5 S SOU EXTENSION 5 FILED Loading...
Aug 22, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 24, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Mar 23, 2025 EX4G S SOU EXTENSION 4 GRANTED Loading...
Mar 23, 2025 EXT4 S SOU EXTENSION 4 FILED Loading...
Mar 23, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 28, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Aug 28, 2024 EX3G S SOU EXTENSION 3 GRANTED Loading...
Aug 28, 2024 EXT3 S SOU EXTENSION 3 FILED Loading...
Aug 28, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 6, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Mar 5, 2024 EX2G S SOU EXTENSION 2 GRANTED Loading...
Mar 5, 2024 EXT2 S SOU EXTENSION 2 FILED Loading...
Mar 5, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jul 28, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 26, 2023 EX1G S SOU EXTENSION 1 GRANTED Loading...
Jul 26, 2023 EXT1 S SOU EXTENSION 1 FILED Loading...
Jul 26, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Apr 11, 2023 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Feb 14, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Feb 14, 2023 PUBO A PUBLISHED FOR OPPOSITION Loading...
Jan 25, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jan 12, 2023 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jan 6, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jan 6, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jan 6, 2023 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Aug 1, 2022 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Aug 1, 2022 GNRT F NON-FINAL ACTION E-MAILED Loading...
Aug 1, 2022 CNRT R NON-FINAL ACTION WRITTEN Loading...
Aug 1, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Nov 8, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Oct 26, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceuticals for treating Alzheimer's Disease, Parkinson's Disease, amyotrophic lateral sclerosis (ALS), Huntington's Disease, epilepsy, spinal cord injury, stroke, cerebral aneurysm, traumatic brain injury, concussion, a tumor, cancer, inflammation, viral and baterial infections, ataxia, brain atrophy, spinal cord atrophy, multiple sclerosis, traumatic spinal cord injury, ischemic or hemorrhagic myelopathy (myelopathy), global ischemia, hypoxic ischemic encephalopathy, embolism, fibrocartilage embolism myelopathy, thrombosis, nephropathy, chronic inflammatory disease, meningitis, and cerebral venous sinus thrombosis

Additional Information

Pseudo Mark
NEURO EXCEL

Classification

International Classes
005